Dogwood Therapeutics, Inc. logo

Dogwood Therapeutics, Inc.(DWTX)

upturn advisory logo
EXPLORE ADVISORIES AND THEIR HISTORY
QUALITY SIGNAL
1-STAR RATING
PASS
LAST CLOSE
$1.11
11/13/2026
(24-hour delay)

Advisory History & Simulated Performance *

*as per simulation (see disclosures)
  • ALL
  • 1Y
  • 1M
  • 1W
  • BUY Advisory
  • SELL Advisory (Profit)
  • SELL Advisory (Loss)
  • Profit
  • Loss
  • PASS (Skip)
Upturn Stock price based on last close iconStock price based on last close
Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Advisory Performance History (Simulated)Advisory Performance History info

Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Upturn Advisory & Investor View for DWTX

11/13/2026: DWTX (1-star) is currently NOT-A-BUY. Pass it for now.

Dogwood Therapeutics is a clinical-stage biopharmaceutical company focused on developing non-opioid therapies for chronic pain and neuropathy. Its primary investment story centers on the clinical progress of its lead candidate, Halneuron, targeting chemotherapy-induced neuropathic pain. Key strengths include a targeted pipeline addressing high unmet medical needs and an experienced management team. However, the company faces substantial risks, including pre-revenue financial losses, heavy clinical trial dependence, and dilution hazards. It suits high-risk growth investors willing to monitor upcoming clinical data readouts and capital-raising updates.

How to Read the Upturn Advisory

The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.

Company fundamentals, valuation, risks, and news provide supporting context about the business.

Investor Fit

Investor styleFitWhy
Growth investorMixed fitThe company offers high-growth optionality tied to clinical pipeline milestones, though it currently lacks commercial revenue.
Momentum investorStrong fit while signal remains positiveThe stock can experience sharp technical movements around clinical data readouts and capital-raising announcements.
Value investorWeak fitPre-revenue biotechnology companies with recurring losses and dilution risks do not fit traditional value metrics.
Dividend investorWeak fitDogwood Therapeutics does not pay dividends and retains all capital to fund clinical research.
Low-risk investorWeak fitClinical-stage biotechnology stocks carry high regulatory, trial, and financial volatility unsuited for conservative capital preservation.

Risk Profile

Risk factorLevelWhy it matters
Price volatilityHighThe stock price swings significantly in response to clinical trial updates, regulatory news, and market sentiment.
Valuation riskHighWithout commercial revenues or earnings, equity valuation is entirely speculative and vulnerable to market corrections.
Competition risk (biopharmaceutical development)Medium / highThe company faces intense competition from well-funded rivals developing alternative pain and neuropathy treatments.
Business qualityMediumAs an early-stage research enterprise, franchise quality remains unproven until a product reaches commercialization.
Dividend incomeLow / noneInvestors receive no dividend income, relying strictly on potential capital appreciation.
Execution riskHighSuccess depends entirely on the complex and unpredictable process of clinical trial execution and regulatory clearance.

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 42.43M USD
Price to earnings Ratio 0.11
1Y Target Price 14
Price to earnings Ratio 0.11
1Y Target Price 14
Volume (30-day avg) 98.1K shares
Beta 2.11
52 Weeks Range 0.90 - 7.04
Updated Date 11/15/2026
52 Weeks Range 0.90 - 7.04
Updated Date 11/15/2026
Dividends yield (FY) -
Basic EPS (TTM) 10.26

Sector & Industry Intelligence

Sector

Healthcare

Bullish
Sentiment
Strong Bullish
Momentum
Momentum Steady
BUY participation
62.6%
Active BUY / eligible
72 / 115
30-Day BUY Count Change
+35
Market state
Strong Bullish

The number of qualifying BUY stocks has remained relatively stable.

Industry

Biotechnology

BUY participation
45.5%
Active BUY / eligible
20 / 44
30-Day BUY Count Change
+13

Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.

Price Behavior

Steep Decline
PRICE PATH

Steep Decline

The stock price has dropped sharply with strong downward pressure.

Highly Choppy
PRICE STABILITY

Highly Choppy

The stock has experienced frequent, large price swings that make its near-term movement less predictable.

Analysis of Past Performance

Type Stock
Historic Profit -68.95%
Avg. Invested days 10
Today’s Advisory PASS
Upturn Advisory Rating upturn star rating icon
Upturn Advisory Performance Upturn Advisory Performance icon 2.0
Stock Returns Performance Upturn Returns Performance icon 1.0
Upturn Profits based on simulation icon Profits based on simulation
Upturn last close icon Last Close 11/13/2026

Upturn Scorecard

Upturn Star Rating

★★★★★
DWTX receives a 2-star rating, supported by solid analyst coverage. The rating is constrained by weak unit economics, soft company fundamentals, and soft quantitative characteristics.

Company Fundamentals

★★★★★
DWTX has soft overall fundamentals (2 stars), with moderate financial health, soft growth momentum, and moderate ownership. In FY2025 versus FY2024, growth and ownership metrics are mixed: negative earnings growth (-177.4%), soft cash generation (FCF margin 0.0%), slightly negative revenue growth (+0.0%).

Financial Health Rating

★★★★★
DWTX's financial health is supported by strong efficiency, including operating-expense and cost-of-revenue discipline (opex 0.0% of revenue). Profitability is weak (1 stars), which helps explain the 3-star overall score.

Growth Momentum Score

★★★★★
DWTX's growth profile is soft, with the least-weak measure being revenue growth at +0.0% FY2025 versus FY2024. By comparison, while earnings growth (-177.4%, negative) and free-cash-flow growth (-77.7%, negative) hold the profile back, so recent growth is not broad-based across the business.

Ownership

★★★★★
Institutional ownership is 10.3% (soft) and 15.6% of outstanding shares are publicly tradable (soft). Insider ownership of 75.25% supports management-shareholder alignment.

Top 5 Institutional Investors

Armistice Capital, LLC 9.22%
Millennium Management LLC 1.01%
Vanguard Capital Management, LLC 0.39%
Geode Capital Management, LLC 0.26%
Vanguard Fiduciary Trust Co 0.18%

Unit Economics (Per $1K Revenue)

★★★★★
DWTX generates approximately $0 of gross profit, $-0 of operating income, and $-0 of free cash flow for every $1,000 of revenue. Based on FY2025 results. Weak margins explain the 1-star rating, with weak cash conversion and weak capital efficiency.

Economic Dimensions

★★★★★
Effective Tax Rate: -0.65% (Tax Credit)

Quantitative Style Profile

★★★★★
DWTX has a High Volatility Profile profile. Weak momentum is the primary drawback, while elevated volatility.

Style Classification

Quality Focused

Value-OrientedHigh VolatilitySmall / Mid Cap Risk

How Company Makes Money

Business areaWhat it includesRetail investor read
Clinical Therapeutics DevelopmentResearch and clinical advancement of non-opioid drug candidates like Halneuron and SP16 for pain and neuropathy.The company currently generates zero revenue and burns cash to test experimental medicines.

Valuation

Trailing PE 0.11
Forward PE -
Enterprise Value 37.98M
Price to Sales(TTM) 424.33
Enterprise Value 37.98M
Price to Sales(TTM) 424.33
Enterprise Value to Revenue 379.85
Enterprise Value to EBITDA 0.22
Shares Outstanding 38.23M
Shares Floating 5.95M
Shares Outstanding 38.23M
Shares Floating 5.95M
Percent Insiders 75.25
Percent Institutions 10.29

Financial Metrics

🧭 Investment Snapshot

Total Revenue (Scale)

Information icon Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.

Net Income (Profit)

Information icon Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.

Free Cash Flow (Cash Strength)

Information icon Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.

📈 Growth & Strength

Operating Income (Core Profit)

Information icon Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.

EBITDA (Cash Earnings)

Information icon Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.

Gross Profit (Unit Profitability)

Information icon Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.

🛡️ Financial Safety

Cash (Liquidity Buffer)

Information icon Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.

Total Debt (Leverage Risk)

Information icon Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.

Net Working Capital (Short-Term Health)

Information icon Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.

🧱 Balance Sheet Strength

Stockholder Equity (Net Worth)

Information icon Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.

Total Assets (Asset Base)

Information icon The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.

Income Before Tax (Pre-Tax Earnings)

Information icon Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.

⚙️ Cost & Drag Factors

Cost of Revenue (Production Cost)

Information icon Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.

Total Operating Expenses (Operating Cost)

Information icon Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.

Income Tax Expense (Tax Drag)

Information icon Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

Form CRS provides a relationship summary of our automated advisory services, flat subscription fees, and conflicts of interest. Form ADV Part 2A brochure contains complete details on services, billing, and disclosures. If any summary differs from our current regulatory filings, the filed Form ADV controls.